Open Access

ARTICLE

Prostate cancer: chemoprevention update 2005

Neil Fleshner, Rami Al Azab

Department of Surgery (Urology), University Health Network and University of Toronto, Ontario, Canada
Address correspondence to Dr. Neil Fleshner, Division of Urology, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2M9 Canada

Canadian Journal of Urology 2005, 12(Suppl.3), 2-4.

Abstract

Introduction: If an agent can slow the growth of existing prostate cancer cells, it remains plausible that it may be effective as an adjunct to surgery, radiation or chemotherapy.
Discussion: Level-1 evidence will be needed in order to definitively prove the efficacy of agents as chemoprevention strategies for prostate cancer. Currently, only finasteride fulfills this criterion. Two major trials are underway that will assess the role of soy, vitamin E and selenium in prostate cancer prevention.
Conclusion: Tantalizing prospects for effective of prostate cancer exist. Fortunately, well-conducted randomized trials will allow us to answer many of these questions within the next 2 to 8 years.

---

Keywords

---